IDP Pharma has closed today a 2M€ private funding round. The company will allocate the funding to start clinical activities of IDP-121 (solid and haem tumors), to complete the formulation of IDP-233 (neuroendocrine tumors) and to exploit its technological platform (IDP Platform).

The company has received further support from RETOS public program (1M€) to advance innovative research in collaboration with CIMA and Univertisy of Navarra.